Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05654532 · ClinicalTrials.gov registry record · Phase 1

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Accutar Biotechnology.

Active
Registry status
Phase 1
Development phase
100
Enrollment target
9
Study locations

NCT05654532 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Accutar Biotechnology. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05654532, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Accutar Biotechnology.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
9
Study locations

Study Summary

This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given safely to participants * Evaluate the safety profile of AC699 * Evaluate the pharmacokinetics of AC699 * Evaluate the effectiveness of AC699

Conditions Studied

Breast Cancer

Interventions

  • DRUG AC699

Study Locations (9)

Florida

  • Site 07 - Orlando
  • Site 02 - Sarasota

Texas

  • Site 03 - Houston
  • Site 09 - San Antonio

Colorado

  • Site 08 - Denver

Maryland

  • Site 06 - Rockville

Tennessee

  • Site 01 - Nashville

Virginia

  • Site 05 - Norfolk

Washington

  • Site 04 - Vancouver

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-12-29
Est. Completion 2026-05-31
Phase Phase 1

Sponsor

Accutar Biotechnology

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05654532

The ClinicalTrials.gov registry entry for NCT05654532 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Accutar Biotechnology, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which AC699 is the first listed.

NCT05654532 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, Texas, Colorado.

Frequently Asked Questions

What is clinical trial NCT05654532 about?

NCT05654532 is a clinical study titled "Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer". This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC699 that can be given sa...

What is the current status of trial NCT05654532?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2022-12-29. Estimated completion is 2026-05-31.

What conditions does trial NCT05654532 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05654532?

The interventions under investigation include: AC699 (DRUG).

Who is sponsoring clinical trial NCT05654532?

This trial is sponsored by Accutar Biotechnology, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05654532 being conducted?

This trial has 9 study locations across Colorado, Florida, Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.